Skip to content

Study · Observational study · n = 187 · 2019

7 results

Liraglutide in a real-world setting: Joint modeling of metabolic response, prediction of efficacy, and cardiovascular risk.

Alonso-Troncoso I, Carollo-Limeres C, Rios-Prego M, Guler I, Cadarso-Suárez C, F-Mariño A

Endocrinologia, diabetes y nutricion6 Dec 2018Cited by 4 (Europe PMC)

PMID30528642 (opens in a new tab)DOI10.1016/j.endinu.2018.09.005 (opens in a new tab)PepBankPUB-30528642
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In real-world patients treated with liraglutide for at least one year, HbA1c decreased significantly in the first 12 weeks and the decrease persisted at 12 and 24 months.

    In plain wordsIn real-world patients using liraglutide, HbA1c fell early and stayed lower at 12 and 24 months.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c reduction over 24 months
    Study

    n = 187

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · at least one yearAs given in this study (human).

    Measurements

    HbA1c decrease
    1.7%
    24 months

    Source sentences

    Summary
    HbA1c levels and weight significantly decreased in the first 12 weeks, and the decrease persisted at 12 and 24 months in all subgroups studied. Mean weight and HbA1c decreases after 24 months were 8.5kg and 1.7% respectively.
    1 context sentence
    Summary · context
    An observational, retrospective cohort study including patients treated with LRG for at least one year (187 patients).
  2. 02HumanObservational studyEfficacy outcome

    In real-world patients treated with liraglutide for at least one year, body weight decreased significantly in the first 12 weeks and the decrease persisted at 12 and 24 months.

    In plain wordsIn real-world patients using liraglutide, weight fell early and stayed lower at 12 and 24 months.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight reduction over 24 months
    Study

    n = 187

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · at least one yearAs given in this study (human).

    Measurements

    Weight decrease
    8.5 kg
    24 months

    Source sentences

    Summary
    HbA1c levels and weight significantly decreased in the first 12 weeks, and the decrease persisted at 12 and 24 months in all subgroups studied. Mean weight and HbA1c decreases after 24 months were 8.5kg and 1.7% respectively.
    1 context sentence
    Summary · context
    An observational, retrospective cohort study including patients treated with LRG for at least one year (187 patients).
  3. 03HumanObservational studyEfficacy outcome

    In real-world patients treated with liraglutide, 42% reached HbA1c below 7% at 12 months.

    In plain wordsIn real-world patients using liraglutide, 42% had HbA1c below 7% at 12 months.

    Peptide
    Liraglutide
    Outcome
    Not applicableHbA1c below 7% at 12 months
    Study

    n = 187

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · at least one yearAs given in this study (human).

    Measurements

    Patients with HbA1c below 7%
    42%
    12 months

    Source sentences

    Summary
    HbA1c values <7% were achieved by 42% of patients at 12 months
    1 context sentence
    Summary · context
    An observational, retrospective cohort study including patients treated with LRG for at least one year (187 patients).
  4. 04HumanObservational studyEfficacy outcome

    In real-world patients treated with liraglutide, 40% reached HbA1c below 7% at 24 months.

    In plain wordsIn real-world patients using liraglutide, 40% had HbA1c below 7% at 24 months.

    Peptide
    Liraglutide
    Outcome
    Not applicableHbA1c below 7% at 24 months
    Study

    n = 187

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · at least one yearAs given in this study (human).

    Measurements

    Patients with HbA1c below 7%
    40%
    24 months

    Source sentences

    Summary
    HbA1c values <7% were achieved by 42% of patients at 12 months and by 40% at 24 months.
    1 context sentence
    Summary · context
    An observational, retrospective cohort study including patients treated with LRG for at least one year (187 patients).
  5. 05HumanObservational studyEfficacy outcome

    In real-world patients treated with liraglutide, treatment allowed a reduction in insulin dose.

    In plain wordsIn real-world patients using liraglutide, insulin doses could be lowered.

    Peptide
    Liraglutide
    Outcome
    DecreaseInsulin dose reduction
    Study

    n = 187

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · at least one yearAs given in this study (human).

    Source sentences

    Summary
    Treatment with LRG allowed for reduction in insulin dose.
    1 context sentence
    Summary · context
    An observational, retrospective cohort study including patients treated with LRG for at least one year (187 patients).
  6. 06HumanObservational studySafety outcome

    In real-world patients treated with liraglutide, no serious adverse events were noted.

    In plain wordsIn real-world patients using liraglutide, no serious side effects were noted.

    Peptide
    Liraglutide
    Outcome
    No significant changeSerious adverse events
    Study

    n = 187

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · at least one yearAs given in this study (human).

    Source sentences

    Summary
    No serious adverse events were noted.
    1 context sentence
    Summary · context
    An observational, retrospective cohort study including patients treated with LRG for at least one year (187 patients).
  7. 07HumanObservational studyEfficacy outcome

    In real-world patients treated with liraglutide, estimated cardiovascular risk decreased from high to moderate-low.

    In plain wordsIn real-world patients using liraglutide, estimated heart risk fell from high to moderate-low.

    Peptide
    Liraglutide
    Outcome
    DecreaseCardiovascular risk
    Study

    n = 187

    Outcome group
    Cardiometabolic risk factors · Cardiovascular
    Studied dose
    Dose not stated · at least one yearAs given in this study (human).

    Source sentences

    Summary
    Cardiovascular risk decreased from high to moderate-low.
    1 context sentence
    Summary · context
    An observational, retrospective cohort study including patients treated with LRG for at least one year (187 patients).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.